Tibetan medicine

PADMA Inc. – Ancient Tibetan Recipes and Swiss Quality. Tibetan medicine products since 1969

PADMA products are unique herbal blends of knowledge and experience carried over centuries of Tibetan medicine and manufactured to the highest Swiss quality standards since 1969. ‘

PADMA combines the ancient science of Tibetan wisdom with modern science, carefully selected raw materials and Swiss quality. Many PADMA products, such as PADMA Basic for blood supply disorders and atherosclerosis, PADMA Digestin for digestive disorders, and PADMA Nervotonin for nervous system and sleep problems, have proven themselves over the years in Estonia, other European countries, and America.

PRODUCTION AND QUALITY

Padma Inc. manufactures medicines and supplements in accordance with the International Standard for Good Manufacturing Practice (GMP) for Medicines. The company undergoes regular official inspections in Switzerland.

PADMA herbal mixtures consist of carefully blended and comminuted herbal components. The company refrains from using additives such as preservatives, flavorings, dyes. It also follows the Tibetan tradition of using only natural and natural ingredients in herbs. the raw materials used meet the very strict official quality requirements applied to each individual plant. Traces of pesticides, heavy metals or molds in plants immediately preclude their use in production. In addition to chemical analysis methods,

PADMA quality specialists also use their own taste and smell. The human sensory organs act as very sensitive tools that complement the chemical test methods in a significant way.

 

RESEARCH

In recent decades, the requirements for registration of the production of medicines and supplements have steadily increased. The purpose of such prescriptions is to ensure the quality, safety and efficacy of health products. The primary goal of PADMA is to make Tibetan pharmacological products available to Western patients within our modern regulatory framework.

Numerous experimental studies and clinical trials have been conducted on PADMA herbal formulations to describe the mechanisms of action of the products and to prove their efficacy. Scientist are currently researching PADMA products at universities and clinics in Switzerland, Austria, Germany, Denmark, Israel and other countries.

Research results are available in the following areas: Recurrent respiratory tract infections Chronic hepatitis B Chronic arthritis Gastrointestinal problems, constipation, flatulence, irritable bowel syndrome Atherosclerosis of the lower limbs. Peripheral arterial disease – PAD or claudication (the main mechanism of arterial atherosclerosis and related atherothrombosis)

TEE LĂ„Ă„NDE

Padma Inc looja, Karl Lutz, osales 1954. aastal Tiibeti traditsioonilise meditsiini loengul Zürichis.Ta vaimustus loengul õpitust nii, et otsustas kaevuda veelgi enam iidse meditsiinisüsteemi kogemustesse ja filosoofiasse. Olles õppinud Tiibeti meditsiini mitu aastat elu Karl Lutzi kokku Dr. Peter Padmajeviga, kes omakorda oli Dr. Sul Tim Badma vennapoeg. Dr. Badma oli kuulus Tiibeti arst, kel õnnestus peatada tol ajal Siberit laastanud tüüfuse epideemia. Tema edust sai ka kuulda Vene Tsaar. Viimane kutsus Dr. Badma Sankt Peterburgi, kus ta avas esimese Tiibeti apteegi läänemaailmas.
Umbes 1960. aastal usaldas Dr. Peter Padmajev oma kuulsa onu retseptid Karl Lutzi hoolde. Saadud materjalide alusel lõi Karl Lutz Tiibeti retseptide uurimisgrupi Zürichis. Teadlased kümnest erinevast riigist uurisid neid ülestähendusi, mille alusel valmis nimekiri näidustuste kohta millal ja kuidas kõnealuseid traditsioonilisi taimesegusid kasutada. Nimekiri näidustuste kohta jagati koos vastvalminud taimsete tablettidega arstidele üle Šveitsi.
Martin Saxeril on valminud suurepärane dokumentaalfilm Tiibeti meditsiini tulekust läände pealkirjaga “Journeys with Tibetan Medicine.”

PADMA INC ASUTAMINE

Innustatuna Šveitsi arstidelt saadud positiivsest tagasisidest asutas Karl Lutz 1969. aastal Padma Inc. ettevõtte, mis hakkas kaasaegsete meetoditega tootma Tiibeti retseptide alusel valmistatud taimseid tablette. 1970. aastal andis Šveitsi tolleaegne ravimiamet “Swissmedic” oma heakskiidu taimsele segule Padma Lax (nr 179). Seitse aastat hiljem sai heakskiidu järgmine toode, Padma 28.
1994. aastal otsustas Karl Lutz minna pensionile ja andis Padma Inc juhtimise üle oma lähedasele kaastöötajale Dr. Herbert Shwablile, Austria bio füüsikule, kes juhib ettevõtet tänase päevani.
Koostöö Padma ja Tiibeti arstide ning institutsioonide vahel on sellest ajast järjest tihenenud. 1999. aastal kolis firma Zürichi lähedale Schwerzenbachi. Tänapäeval annab ettevõte tööd ligi viiekümnele inimesele.